Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Taltz® (ixekizumab)
Medicina y Salud Pública
Regresar
¿No tienes cuenta? Regístrate aquí